Article Text


DDF plenary session
OC-041 IL28B haplotypes and IP-10 predict treatment response for recurrent HCV post transplant
  1. D Joshi1,
  2. I Carey1,
  3. M Bruce2,
  4. A Barnabas1,
  5. S Knighton1,
  6. M Heneghan1,
  7. V Aluvihare1,
  8. A Suddle1,
  9. N Heaton1,
  10. J O'Grady1,
  11. K Agarwal1
  1. 1Institute of Liver Studies, King's College Hospital, London, UK
  2. 2Institute of Studies, King's College Hospital, London, UK


Introduction Hepatitis C virus (HCV) recurrence post liver transplant (LT) is universal. Sustained virological response (SVR) rates post LT with pegylated interferon (PEG-IFN) and ribavirin (RIB) range between 26% and 50% and are associated with significant side effects. Single nucleotide polymorphisms (SNPs) rs12979860 near the IL28B gene predict response to treatment. Strong immune T helper type 1 responses towards HCV determine also play an integral role in the outcome of infection. Interferon γ inducible protein 10 (IP-10) has been shown to correlate with treatment response in HCV mono-infection and HIV co-infected patients but limited data are available for patients in the post LT period. Our aim was to investigate whether SNPs near IL28B gene rs12979860 and pre-treatment plasma levels of IP-10 can predict treatment response in patients with recurrent HCV post LT.

Methods Pre-treatment plasma samples were studied in HCV patients post LT. Plasma levels of IP-10 (pg/ml) was measured by ELISA. rs12979860 were tested by direct sequencing. All patients were treated with PEG-IFN α 2a and weight based RIB for a minimum of 48 weeks irrespective of genotype. Virological response was divided into SVR, null-response (NR) and responder relapse (RR). All results are presented as medians (range).

Results 41 patients (34 male) with recurrent HCV (49% genotype one disease) were treated at a median time of 43 months (3–133) post LT. 71% of patients were maintained on tacrolimus monotherapy. Nine patients had been treated previously with PEG-IFN and RIB. Median baseline HCV viral load was 2.35E6 IU/ml. 78% of patients were commenced on a low accelerated dosage regimen (median dose PEG 135 μg, median dose RIB 800 mg). Rs12979860 haplotype CC was present in 24% (8×SVR, 2×RR), CT 59% (10×SVR, 9×NR, 5×RR) and TT in 17% (1×SVR, 6×NR). SVR was achieved by 19 patients (46%), 15 patients were NR (37%) and 7 were RR (17%). Baseline IP-10 levels correlated with serum AST (r=0.48, p=0.003), ALT (r=0.36, p=0.05), fibrosis score (r=0.33, p=0.04) and necro-inflammatory score (r=0.54, p=0.001). IP-10 levels were lower in those who achieved a SVR (116 vs 490, p<0.0001). IP-10 levels were higher in the NR group compared to the SVR and RR groups (545 vs 116 vs 320, p<0.0001). AUROC analysis identified IP-10 to be a significant predictor of SVR (0.84, 0.71–0.97, p<0.0001). CC haplotype and IP-10 <154 pg/ml had a 100% PPV for SVR.

Conclusion Our data demonstrates that patients with a lower baseline IP-10 level are more likely to achieve a SVR. The IL28B CC haplotype in conjunction with a low IP-10 level predicts treatment success in recurrent HCV post LT.

Competing interests None declared.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.